

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Metoprolol Succinate Extended Release Tablets USP

Seloken® XL 25, 50, 100 & 200*

Composition

Each extended release film coated tablet contains:

| | |
|--|-----------------|
| Metoprolol Succinate USP | 23.75 mg |
| equivalent to Metoprolol Tartrate | 25 mg |
| Metoprolol Succinate USP | 47.5 mg |
| equivalent to Metoprolol Tartrate | 50 mg |
| Metoprolol Succinate USP | 95 mg |
| equivalent to Metoprolol Tartrate | 100 mg |
| Metoprolol Succinate USP | 190 mg |
| equivalent to Metoprolol Tartrate | 200 mg |

Pharmaceutical form

Tablets with controlled release of metoprolol.

Seloken XL 25mg tablet is white to off-white, oval, scored on both sides and marked A/b on one side.

Seloken XL 50 mg tablet is white to off-white, circular, scored on one side and marked ^AmO on the other side.

Seloken XL 100 mg tablet is white to off-white, circular, scored on the one side and marked ^Ams on the other side.

Seloken XL 200 mg tablet is white to off-white, oval, scored and marked ^AmY on one side.

Indications

Hypertension: to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity.

Angina pectoris.

Stable symptomatic chronic heart failure with impaired systolic left ventricular function as an adjunct to existing heart failure therapy.

Prevention of cardiac death and reinfarction after the acute phase of myocardial infarction.

Cardiac arrhythmias especially including supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and in ventricular extrasystoles.

Functional heart disorders with palpitations.

Migraine prophylaxis.

Dosage and method of administration

Seloken XL is intended for once daily treatment and is preferably taken in the morning. The Seloken XL tablet should be swallowed with liquid. The tablets and the divided halves should not be chewed or crushed. Concomitant intake of food does not influence the bioavailability.

Dosage should be adjusted to avoid bradycardia.

Hypertension

The recommended dosage in patients with mild to moderate hypertension is 50 mg Seloken XL given once daily. In patients not responding to 50 mg the dose could be increased to 100-200 mg once daily and/or combined with other antihypertensive agents.

Angina pectoris

The recommended dosage is 100-200 mg Seloken XL given once daily. If needed, Seloken XL can be combined with other antianginal agents.

Stable symptomatic chronic heart failure with impaired systolic left ventricular function as an adjunct to existing heart failure therapy

The patients should have a stable chronic heart failure, without acute failure for the latest 6 weeks and an essentially unchanged basal therapy for the latest 2 weeks.

Treatment of heart failure with beta-blockers may sometimes cause a temporary exacerbation of the symptoms picture. In some cases, it is possible to continue the therapy or reduce the dose, and in other cases it may be necessary to discontinue the treatment. Initiation of Seloken XL therapy in patients with severe heart failure (NYHA IV) should only be made by physicians especially trained in treatment of heart failure (see *Special Warnings and Precautions for Use*).

Dosage in patients with stable heart failure, function class II:

A recommended initial dosage for the first two weeks is 25 mg once daily. After two weeks, the dose can be increased to 50 mg once daily, and thereafter it can be doubled every second week. The target dose for long-term treatment is 200 mg once daily.

Dosage in patients with stable heart failure, function classes III-IV:

Recommended initial dose is 12.5 mg (half a 25 mg tablet) given once daily. The dose should be individually adjusted, and the patient should be closely monitored during the increase of the dosage as heart failure symptoms may be aggravated in some patients. After 1-2 weeks, the dose can be raised to 25 mg given once daily. Then, after further two weeks, the dosage can be increased to 50 mg given once daily. In those patients who tolerate a higher dose, the dosage can be doubled every second week up to a maximal dose of 200 mg daily.

In case of hypotension and/or bradycardia, decrease in concomitant medication or lowering of the Seloken XL dose may be necessary. Initial hypotension does not necessarily mean that the dose of Seloken XL cannot be tolerated in chronic treatment, but the dose must not be raised until the condition has been stabilised, and increased control of renal function, among other things, may be required.

Cardiac arrhythmias

The recommended dosage is 100-200 mg Seloken XL given once daily.

Prophylactic treatment after myocardial infarction

Long-term oral treatment with metoprolol in doses of 200 mg given once daily has been shown to reduce the risk of death (including sudden death), and to reduce the risk of reinfarction (also in patients with diabetes mellitus).

Functional heart disorders with palpitations

The recommended dosage is 100 mg once daily. If needed, the dose can be increased to 200 mg.

Migraine prophylaxis

The recommended dosage is 100-200 mg once daily.

Impaired renal function

Dose adjustment is not needed in patients with impaired renal function.

Impaired hepatic function

Dose adjustment is normally not needed in patients suffering from liver cirrhosis because metoprolol has a low protein binding (5-10 %). When there are signs of serious impairment of liver function (e.g. shunt-operated patients) a dose reduction should be considered.

Elderly

Dose adjustment is not needed in the elderly.

Children

There is limited experience with Seloken XL treatment in children.

Contraindications

Atrioventricular block of second or third degree, patients with unstable decompensated cardiac heart failure (pulmonary oedema, hypoperfusion or hypotension), and patients with continuous or intermittent inotropic therapy acting through beta-receptor agonism; marked clinically relevant sinus bradycardia, sick-sinus syndrome, cardiogenic shock, severe peripheral arterial circulatory disorder.

Metoprolol should not be given to patients with suspected acute myocardial infarction as long as the heart rate is <45 beats/min, the P-Q interval is > 0.24 sec or the systolic blood pressure is <100 mm Hg.

Seloken XL is contra-indicated in patients who have shown hypersensitivity to any component of the product or to other β -blockers.

Special warnings and precautions for use

Intravenous administration of calcium antagonists of the verapamil-type should not be given to patients treated with β -blockers.

Generally when treating patients with asthma, concomitant therapy with a β_2 -agonist (tablet and/or aerosol) should be administered. The dosage of β_2 -agonists may require adjustment (increase) when treatment with Seloken XL is started. The risk of Seloken XL interfering with β_2 -receptors is however less than with conventional tablet formulations of β_1 selective blockers.

During treatment with Seloken XL, the risk of interfering with carbohydrate metabolism or masking hypoglycaemia is likely to be less than during treatment with conventional tablet formulations of β_1 -selective blockers and much less than with nonselective β -blockers.

Patients suffering from heart failure should have their decompensation treated both before and during treatment with Seloken XL.

Very rarely, a pre-existing A-V conduction disorder of moderate degree may become aggravated (possibly leading to A-V block).

If the patients develop increasing bradycardia, Seloken XL should be given in lower doses or gradually withdrawn.

Seloken XL may aggravate the symptoms of peripheral arterial circulatory disorders, mainly due to its blood pressure lowering effect.

Where Seloken XL is prescribed for a patient known to be suffering from a pheochromocytoma, an alphablocker should be given concomitantly.

Prior to surgery the anaesthetist should be informed that the patient is receiving Seloken XL. It is not recommended to stop β -blocker treatment in patients undergoing surgery.

Efficacy/safety data from controlled clinical studies in severe stable symptomatic heart failure (NYHA class IV) are limited. Treatment of heart failure in these patients should therefore only be initiated by physicians with especial experience and training in this area (see Dosage and Method of Administration).

Patients with symptomatic heart failure in association with acute myocardial infarction and unstable angina pectoris were excluded from the study on which the indication of heart failure is founded. Efficacy/safety conditions have therefore not been documented. Use in unstable, decompensated heart failure is contraindicated (see Contraindications).

Abrupt interruption of the medication is to be avoided. Sudden withdrawal of beta-blockade is hazardous, especially in high-risk patients, and may aggravate chronic heart failure as well as increase the risk of myocardial infarction and sudden death. Any withdrawal of Seloken XL should therefore, if possible, be made gradually over at least two weeks when the dose is reduced by half in each step, down to the final dose when a 25mg tablet is reduced to half a tablet. The final dose should be given for at least four days before discontinuation. If symptoms occur, a slower withdrawal rate is recommended.

In patients taking β -blockers anaphylactic shock assumes a more severe form.

Interactions

Patients receiving concomitant treatment with sympathetic ganglion blocking agents, other beta-blockers (i.e. eye drops), or Mono Amine Oxidase (MAO) inhibitors should be kept under close surveillance.

If concomitant treatment with clonidine is to be discontinued, the betablocker medication should be withdrawn several days before clonidine.

A watch should be kept for possible negative inotropic and chronotropic effects when metoprolol is given together with calcium antagonists of the verapamil and diltiazem type and/or antiarrhythmic agents. In patients treated with β -blockers intravenous administration of calcium antagonists of the verapamil type should not be given.

Betablockers may enhance the negative inotropic and negative dromotropic effect of antiarrhythmic agents (of the quinidine type and amiodarone).

In patients receiving β -blocker therapy, inhalation anaesthetics enhance the cardiodepressant effect.

Enzyme-inducing and enzyme-inhibiting substances may exert an influence on the plasma level of metoprolol. The plasma concentration of metoprolol is lowered by rifampicin and may be raised by cimetidine, alcohol and hydralazine and selective serotonin reuptake inhibitors (SSRIs) e.g. paroxetine, fluoxetine and sertraline.

Concomitant treatment with indomethacin or other prostaglandin synthetase inhibiting drugs may decrease the antihypertensive effect of β -blockers.

Under certain conditions, when adrenaline is administered to patients treated with β -blockers, cardioselective β -blockers interfere much less with blood pressure control than nonselective β blockers.

The dosages of oral antidiabetics may have to be re-adjusted in patients receiving β -blockers.

320 mm

Use in pregnancy and lactation

As with most drugs, Seloken XL should not be given during pregnancy and lactation unless its use is considered essential. As with all antihypertensive agents, β -blockers may cause side-effects, e.g. bradycardia, in the foetus and in the newborn and breast-fed infant.

The amount of metoprolol ingested via breast-milk, however, seems to be negligible as regards β -blocking effect in the infant if the mother is treated with metoprolol in doses within the normal therapeutic range.

Effects on ability to drive and use machines

Patients should know how they react to Seloken XL before they drive or use machines because occasionally dizziness or fatigue may occur.

Undesirable effects

Seloken XL is well tolerated and adverse reactions have generally been mild and reversible. The following events have been reported as adverse events in clinical trials or reported from routine use, mostly with conventional Betaloc (metoprolol tartrate). In many cases a relationship to treatment with Betaloc has not been established. The following definitions of frequencies are used: Very common ($\geq 10\%$), common (1-9.9%), uncommon (0.1-0.9%), rare (0.01-0.09%) and very rare ($< 0.01\%$).

Cardiovascular system

Common: Bradycardia, postural disorders (very rarely with syncope), cold hands and feet, palpitations.

Uncommon: Transient deterioration of heart failure symptoms, AV-block I, oedema, precordial pain.

Rare: Disturbances of cardiac conduction, cardiac arrhythmias.

Very rare: Gangrene in patients with pre-existing severe peripheral circulatory disorders.

Central nervous system

Very common: Fatigue.

Common: Dizziness, headache.

Uncommon: Paraesthesiae, muscle cramps.

Gastrointestinal

Common: Nausea, abdominal pain, diarrhoea, constipation.

Uncommon: Vomiting.

Rare: Dry mouth.

Haematologic

Very rare: Thrombocytopenia.

Hepatic

Rare: Liver function test abnormalities.

Very Rare: Hepatitis.

Musculoskeletal

Very rare: Arthralgia

Metabolism

Uncommon: Weight gain.

Psychiatric

Uncommon: Depression, concentration impaired, somnolence or insomnia, nightmares.

Rare: Nervousness, anxiety, impotence/sexual dysfunction.

Very rare: Amnesia/memory impairment, confusion, hallucinations.

Respiratory

Common: Dyspnoea on exertion.

Uncommon: Bronchospasm.

Rare: Rhinitis.

Sense organs

Rare: Disturbances of vision, dry and/or irritated eyes, conjunctivitis.

Very rare: Tinnitus, taste disturbances.

Skin

Uncommon: Rash (in the form of urticaria psoriasiform and dystrophic skin lesions), increased sweating.

Rare: Loss of hair.

Very rare: Photosensitivity reactions, aggravated psoriasis.

Overdosage

Symptoms

Overdosage of Seloken XL may lead to severe hypotension, sinus bradycardia, atrioventricular block, heart failure, cardiogenic shock, cardiac arrest, bronchospasm, impairment of consciousness/coma, nausea, vomiting, and cyanosis.

Concomitant ingestion of alcohol, antihypertensives, quinidine or barbiturates may aggravate the patient's condition.

The first manifestations of overdosage may be observed 20 minutes to 2 hours after the drug's ingestion.

Management

Activated charcoal, if necessary gastric lavage. In the presence of severe hypotension, bradycardia, and impending heart failure, administer a β_1 -agonist (e.g. prenalterol) intravenously at 2-5 minutes intervals or as continuous infusion until the desired effect is achieved. Where a selective β_1 -agonist is not available, dopamine may be used; or atropine sulphate i.v. may be used in order to block the vagus nerve.

If a satisfactory effect is not achieved, other sympathomimetic agents, such as dobutamine may be used, or noradrenaline may be given.

Glucagon in a dose of 1-10 mg can also be administered. Pacemaker may be necessary. To combat bronchospasm, a β_2 -agonist can be given i.v.

Observe that the dosages of drugs (antidotes) needed to treat overdose of β -blockade are much higher than normally recommended therapeutic dosages. This is because β -receptors are occupied by the β -blocker.

Pharmacodynamic properties

Metoprolol is a β_1 -selective betablocker, i.e. it blocks β_1 -receptors at doses much lower than those needed to block β_2 -receptors.

Metoprolol has an insignificant membranestabilising effect and does not display partial agonistic activity.

Metoprolol reduces or inhibits the agonistic effect on the heart of catecholamines (which are released during physical and mental stress). This means that the usual increase in heart rate, cardiac output, cardiac contractility and blood pressure, produced by the acute increase in catecholamines, is reduced by metoprolol. During high endogenous adrenaline levels metoprolol interferes much less with blood pressure control than non-selective β -blockers.

When mandatory, Seloken XL, in combination with a β_2 -agonist, may be given to patients with symptoms of obstructive pulmonary disease. When given together with a β_2 -agonist, Seloken XL in therapeutic doses interferes less than non-selective β -blockers with the β_2 -mediated broncho-dilation caused by the β_2 -agonist.

Seloken XL gives an even plasma concentration time profile and effect (β_1 -blockade) over 24 hours in contrast to conventional tablet formulations of β_1 -selective blockers.

Due to the lack of pronounced peaks in plasma concentration, the clinical β_1 -selectivity is improved with the Seloken XL formulation when compared to conventional tablet formulations of β_1 -selective blockers. Furthermore the potential risk for peak plasma concentration related side effects, such as bradycardia and leg fatigue is reduced.

Seloken XL interferes less with insulin release and carbohydrate metabolism than do nonselective β -blockers.

Seloken XL interferes much less with the cardiovascular response to hypoglycaemia than do non-selective β -blockers.

Short term studies have shown that Seloken XL may cause a slight increase in triglycerides and a decrease in free fatty acids in the blood. In some cases, a small decrease in the high density lipoproteins (HDL) fraction has been observed, although to a lesser extent than that following nonselective β -blockers. However, a significant reduction in total serum cholesterol levels has been demonstrated after metoprolol treatment in one study conducted over several years.

Quality of life is maintained, uncompromised or improved during treatment with Seloken XL.

An improvement in quality of life has been observed after metoprolol treatment in patients after myocardial infarction and in patients with idiopathic dilated cardiomyopathy.

In MERIT-HF, a survival study comprising 3991 patients with chronic heart failure (NYHA II-IV) and decreased ejection fraction (≤ 0.40), Seloken XL has been shown to increase survival and to reduce the number of hospitalisations. In long-term treatment the patients experience a general improvement of symptoms (NYHA class and Overall Treatment Evaluation score).

In addition, it has been shown that Seloken XL therapy increases the ejection fraction and reduces the left ventricular end systolic and end diastolic volumes.

Pharmacokinetic properties

Absorption and distribution

Seloken XL is completely absorbed after oral administration. Owing to an extensive first-pass effect, the systemic bioavailability of metoprolol from a single oral dose is approximately 50%. The bioavailability is reduced by about 20-30% for the controlled release preparation compared with a conventional tablet, but this has been demonstrated to be of no significance for clinical efficacy, since the area under the effect curve (AUEC) for heart rate is the same as with conventional tablets. The plasma protein binding of metoprolol is low, approximately 5-10%.

Metabolism and elimination

Metoprolol undergoes oxidative metabolism in the liver. Three main metabolites have been identified, though none of them have a beta-blocking effect of clinical importance.

As a rule, over 95% of an oral dose can be recovered in the urine. About 5% of the given dose is excreted in the urine in unchanged form, this figure rising up to 30% in isolated cases. The elimination half-life of metoprolol in plasma averages 3.5 hours (extremes: 1 and 9 hours). The total clearance rate is approximately 1 litre/minute.

Elderly show no significant changes in the pharmacokinetics of metoprolol as compared with young persons. The systemic bioavailability and elimination of metoprolol is unchanged in patients with reduced renal function. The excretion of metabolites, however, is reduced. Significant accumulation of metabolites was observed in patients with a glomerulus filtration rate (GFR) of less than 5 ml/min. This accumulation of metabolites, however, does not increase the betablockade.

Due to its low protein binding the pharmacokinetics of metoprolol is little effected by decreased liver function. However, in patients with severe liver cirrhosis and a portacava shunt the bioavailability of metoprolol may increase and the total clearance may be reduced. Patients with a portacaval anastomosis had a total clearance of approximately 0.3 litres/min and area under the plasma concentration-time curve (AUC) values up to 6 times higher than in healthy subjects.

Pharmaceutical particulars

List of excipients

Ethylcellulose, hydroxypropyl cellulose, hypromellose, microcrystalline cellulose, paraffin, macrogol, silicon dioxide, sodium stearyl fumarate, titanium dioxide (E 171).

Shelf Life

Please see outer pack

Presentation

Seloken XL 25mg, 50mg, 100mg

please refer to outer carton for pack size.

*Seloken XL 200mg currently not available.

Special precautions for storage

Do not store above 30°C

Date of revision of the text

January 2001

For further information:

AstraZeneca Pharma India Limited
12th Mile, Bellary Road, Bangalore-560 063.

34-141-58

